Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis

Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis

Background Delanzomib, a novel proteasome inhibitor, has demonstrated promising efficacy and antitumor ability in human multiple myeloma cell lines and patient‐derived cells. However, the potential therapeutic effects of delanzomib on breast cancer remain unknown. In this study, we show that delanzo...

Full description

Bibliographic Details
Main Authors: Mopei Wang, Li Liang, Jiaxiong Lu, Yang Yu, Yanling Zhao, Zhenfeng Shi, Hui Li, Xin Xu, Yuxian Yan, Yan Niu, Zhentao Liu, Lin Shen, Hong Zhang
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:Thoracic Cancer
Subjects:
Breast Neoplasms
Proteasome Inhibitors
Delanzomib
Tumor Suppressor Protein p53
Online Access:https://doi.org/10.1111/1759-7714.13030

Internet

https://doi.org/10.1111/1759-7714.13030

Similar Items